NGM BIOPHARMACEUTICALS INC — Operating Income by Fiscal Year
7 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/89346e8e-bec2-4726-97c5-3c6221dcc08c/serie/operating-income
| Fiscal year | Operating Income | Period | Evidence |
|---|---|---|---|
| FY 2023 | $-151.5M | 2023-01-01 – 2023-12-31 | evidence 0001628280-24-010232 |
| FY 2022 | $-166.2M | 2022-01-01 – 2022-12-31 | evidence 0001628280-23-005569 |
| FY 2021 | $-120.7M | 2021-01-01 – 2021-12-31 | evidence 0001628280-22-004526 |
| FY 2020 | $-103.8M | 2020-01-01 – 2020-12-31 | evidence 0001564590-21-013179 |
| FY 2019 | $-49.3M | 2019-01-01 – 2019-12-31 | evidence 0001564590-20-011422 |
| FY 2018 | $-4.3M | 2018-01-01 – 2018-12-31 | evidence 0001564590-20-011422 |
| FY 2017 | $-17.4M | 2017-01-01 – 2017-12-31 | evidence 0001564590-20-011422 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
NGM BIOPHARMACEUTICALS INC — all facts · Revenue · Net Income